Secretome Therapeutics, a biotechnology company advancing therapies derived from neonatal cardiac progenitor cells (nCPCs), announced the successful closing of a $20.4 million round of financing. This funding will enable initiation of clinical trials for its lead asset, STM-01, and further advance its innovative pipeline in the area of heart health.
“We are grateful to have investors who share our vision and whose support enables Secretome to become a world-class drug development company,” said Vinny Jindal, Co-Founder, President, and CEO of Secretome Therapeutics. “Stem cells have shown extraordinary therapeutic potential, but challenges that include manufacturing inconsistencies have limited their broader application. Our neonatal CPC platform delivers unmatched consistency and potency, positioning Secretome to become a clear leader in this emerging area of medicine.”
The capital raised in this round will support operations through mid-2026 and fund key initiatives, including:
- Clinical Trials: Launching two Phase 1 trials of STM-01 in HFpEF (heart failure with preserved ejection fraction) and DCM (dilated cardiomyopathy), with proof-of-concept data expected in Q3 2025.
- Manufacturing Scale-Up: Transitioning STM-01 manufacturing to 3-dimensional bioreactor technology.
- Pipeline Development: Advancing STM-21 and other preclinical programs to address inflammatory conditions.
- Regulatory Engagement: Defining the regulatory pathway for STM-01 in orphan indications.
- Intellectual Property: Submitting patents on next-generation cell and secretome products following the issuance of composition patents for STM-01 and STM-21.
The therapies that Secretome Therapeutics is developing, are aimed at improving heart health — addressing life-threatening cardiovascular diseases and conditions driven by inflammation.
